Search | Clinical Trials Finder

Conditions: Fabry Disease
Interventions: Venglustat (GZ402671), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more

Conditions: Scalp Psoriasis
Interventions: Betamethasone Scalp Suspension 0.064%;0.0005%, Taclonex®, Placebo topical suspension; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Scalp Psoriasis
Interventions: DSXS topical, Vehicle topical; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 371 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Heart Failure
Interventions: GSK2798745, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Depression, Major Depressive Disorder
Interventions: Levomilnacipran ER, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 30
States / cities: Beverly Hills, California • Encino, California • Garden Grove, California + 26 more

Conditions: ACL Injury, ACL Tears, ACL Surgery
Interventions: Tranexamic Acid (TXA), Placebo; Drug
Lead sponsor: Campbell Clinic; Other
Eligibility: 14 Years to 22 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Evanston, Illinois • Chesterfield, Missouri • Durham, North Carolina + 3 more

Conditions: NSAIDs, Upper GI Symptoms
Interventions: Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 31
States / cities: Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 28 more

Conditions: Adenocarcinoma of the Prostate
Interventions: Muscadine Plus, Placebos; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 13
States / cities: Duarte, California • La Jolla, California • Aurora, Colorado + 10 more

Conditions: Rheumatoid Arthritis
Interventions: TCK-276, TCK-276 Placebo; Drug
Lead sponsor: Teijin America, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Tustin, California • Doral, Florida • Miami, Florida + 3 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 116
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 43
States / cities: Little Rock, Arkansas • Los Angeles, California • Mission Viejo, California + 37 more

Conditions: Healthy
Interventions: Betaine, BCAA Big 6, Placebo; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 8
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 40
States / cities: Downy, California • Fountain Valley, California • Fullerton, California + 37 more

Conditions: Obesity, Overactive Bladder, Incontinence
Interventions: Trospium Chloride, Extended Release (XR), placebo; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: La Mesa, California

Conditions: Major Depressive Disorder (MDD)
Interventions: Radafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 29
States / cities: Little Rock, Arkansas • Newport Beach, California • Farmington, Connecticut + 25 more

Conditions: Healthy Volunteers
Interventions: E2511, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV Infections
Interventions: Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical Non-steroidal anti-inflammatory drug (NSAID), Topical steroid, Topical NSAID placebo, Recombinant human hyaluronidase PH20 (rHuPH20), Topical steroid placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 79
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more

Conditions: Major Depressive Disorder
Interventions: OPC-34712, Placebo, ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 50
States / cities: Arcadia, California • Beverly Hills, California • Escondido, California + 43 more

Conditions: Schizophrenia, Negative Symptoms, Cognitive Dysfunction
Interventions: TC-5619, Placebo; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 22
States / cities: Garden Grove, California • Glendale, California • Long Beach, California + 19 more

Conditions: Osteoarthritis, Knee
Interventions: RHH646, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Lincoln, California • Winter Park, Florida • Houston, Texas + 1 more

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: Rapamycin, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 55 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity, Metabolic Syndrome, Diabetes, Aging
Interventions: resveratrol, placebo, Calorie Restriction; Dietary Supplement · Other · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

Extended Oral Tranexamic Acid After Anterior Cruciate Ligament Reconstruction

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Muscadine Plus (MPX) In Men With Prostate Cancer

A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

The Effects of Pre-Loaded Betaine Supplementation on Thermoregulation and Exercise Metabolism in the Heat

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

Safety and Efficacy of RHH646 for Knee Osteoarthritis

Rapamycin - Effects on Alzheimer's and Cognitive Health

Effect of Resvida, a Comparison With Calorie Restriction Regimen